BNET Industries

Regeneron Pharmaceuticals Inc.

(REGN) is in the Pharma Industry

Market Cap:$1.4B
Last Fiscal Year Sales:$238.4M
  • Public
  • US
Dow Jones Description

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. We currently have one marketed product: ARCALYST ® (rilonacept) Injection for Subcutaneous Use, which is now available for prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. We also have six clinical development programs, including three late-stage clinical programs. Our late stage programs are aflibercept (VEGF Trap), which is being developed in oncology in collaboration with the sanofi-aventis Group, VEGF Trap-Eye, which is being developed in eye diseases using intraocular delivery in collaboration with Bayer HealthCare LLC, and ARCALYST which is being developed for the treatment of gout. Our earlier stage clinical programs are REGN88, an antibody to the interleukin-6 receptor (IL-6R), which is being developed in rheumatoid arthritis, REGN421, an antibody to Delta-like ligand-4 (Dll4), which is being developed in oncology, and REGN475, an antibody to Nerve Growth Factor (NGF), which is being developed for the treatment of pain. All three of these antibodies are being developed in collaboration with sanofi-aventis. ...

Number of Employees 919
Contact Information

777 Old Saw Mill River Rd

Tarrytown, New York 10591-6717

regeneron.com

(914) 345-7400

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Big Pharma Willing to Pay for Biotech Innovation

    11/15/09 - Joint Venture / Alliance - View Story

  • Regeneron Extends Monoclonal Antibody Collaboration With Sanofi-Aventis - Update

    11/10/09 - Joint Venture / Alliance - View Story

  • Regeneron Reports Third Quarter 2009 Financial and Operating Results

    11/03/09 - Joint Venture / Alliance - View Story

  • Regeneron Posts Narrower Q3 Loss - Update

    11/03/09 - Financial Announcement - View Story

  • BUYINS.NET: REGN, EGLE, VG, SSS, DSCO, SRDX Expected To Be Lower After Earnings Releases on...

    11/02/09 - Joint Venture / Alliance - View Story

  • INTERVIEW-Regeneron aims for chink in Avastin's armor

    9/16/09 - Joint Venture / Alliance - View Story

  • Regeneron shares slip on halt to cancer study

    9/14/09 - Bond / Stock Rating - View Story

  • Regeneron to not submit ovarian cancer drug data for accelerated approval; signs two royalty deals...

    6/11/09 - Joint Venture / Alliance - View Story

News & Analysis

regeneron pharmaceuticals inc. - All News and Analysis

advertisement
Click Here
     REGN $18.66 +0.08 (0.43% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 573,050
Shares Outstanding 80.49M
Market Cap 1.5B
Year High 23.49
Year Low 11.81
Earnings Per Share -0.82
P/E Ratio -22.76
Dividend N/A
Yield N/A
IndustryTop Rated
advertisement